Jazz Pharmaceuticals JAZZ Net gains (losses) deferred
Net gains (losses) deferred at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's net gains (losses) deferred.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's net gains (losses) deferred?
- Jazz Pharmaceuticals (JAZZ) reported net gains (losses) deferred of $100K in Q1 2026.
- How has Jazz Pharmaceuticals's net gains (losses) deferred changed year-over-year?
- Jazz Pharmaceuticals's net gains (losses) deferred increased by 125.0% year-over-year, from -$400K to $100K.
- What does net gains (losses) deferred mean?
- Unrealized gains or losses on hedges that are waiting to be recognized in the income statement.
- How do you interpret net gains (losses) deferred?
- A large balance indicates significant ongoing hedging activity and potential future impacts on earnings as these amounts are reclassified.
- How does net gains (losses) deferred compare across companies?
- Standard for companies with active treasury hedging programs.